Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
Leukemia
Mauro, Michael J MJ; Hughes, Timothy P TP; Kim, Dong-Wook DW; Rea, Delphine D; Cortes, Jorge E JE; Hochhaus, Andreas A; Sasaki, Koji K; Breccia, Massimo M; Talpaz, Moshe M; Ottmann, Oliver O; Minami, Hironobu H; Goh, Yeow Tee YT; DeAngelo, Daniel J DJ; Heinrich, Michael C MC; Gómez-García de Soria, Valle V; le Coutre, Philipp P; Mahon, Francois-Xavier FX; Janssen, Jeroen J W M JJWM; Deininger, Michael M; Shanmuganathan, Naranie N; Geyer, Mark B MB; Cacciatore, Silvia S; Polydoros, Fotis F; Agrawal, Nithya N; Hoch, Matthias M; Lang, Fabian F
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Journal Of Hematology & Oncology
Jiang, Qian Q; Li, Zongru Z; Qin, Yazhen Y; Li, Weiming W; Xu, Na N; Liu, Bingcheng B; Zhang, Yanli Y; Meng, Li L; Zhu, Huanling H; Du, Xin X; Chen, Suning S; Liang, Yang Y; Hu, Yu Y; Liu, Xiaoli X; Song, Yongping Y; Men, Lichuang L; Chen, Zi Z; Niu, Qian Q; Wang, Hengbang H; Lu, Ming M; Yang, Dajun D; Zhai, Yifan Y; Huang, Xiaojun X
Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining.
Frontiers In Oncology
Curik, Nikola N; Polivkova, Vaclava V; Burda, Pavel P; Koblihova, Jitka J; Laznicka, Adam A; Kalina, Tomas T; Kanderova, Veronika V; Brezinova, Jana J; Ransdorfova, Sarka S; Karasova, Dominika D; Rejlova, Katerina K; Bakardjieva, Marina M; Kuzilkova, Daniela D; Kundrat, David D; Linhartova, Jana J; Klamova, Hana H; Salek, Cyril C; Klener, Pavel P; Hrusak, Ondrej O; Machova Polakova, Katerina K
Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis.
Hematology, Transfusion And Cell Therapy
Küçükyurt, Selin S; Kelezoğlu, Alihan A; Elverdi, Tuğrul T; Özmen, Deniz D; Ar, Muhlis Cem MC; Eşkazan, Ahmet Emre AE
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Asian Pacific Journal Of Cancer Prevention : Apjcp
Iqbal, Zafar Z; Absar, Muhammad M; Mahmood, Amer A; Aleem, Aamer A; Iqbal, Mudassar M; Jameel, Abid A; Akhtar, Tanveer T; Karim, Sajjad S; Rasool, Mahmood M; Mirza, Zeenat Z; Khalid, Muhammad M; Akram, Afia Muhammad AM; Sabar, Muhammad Farooq MF; Khalid, Ahmad M AM; Aljarrah, Khalid K; Iqbal, Janhangir J; Khalid, Muhammad M; Shah, Ijaz H IH; Alanazi, Nawaf N
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.
Ebiomedicine
Schneeweiss-Gleixner, Mathias M; Byrgazov, Konstantin K; Stefanzl, Gabriele G; Berger, Daniela D; Eisenwort, Gregor G; Lucini, Chantal Blanche CB; Herndlhofer, Susanne S; Preuner, Sandra S; Obrova, Klara K; Pusic, Petra P; Witzeneder, Nadine N; Greiner, Georg G; Hoermann, Gregor G; Sperr, Wolfgang R WR; Lion, Thomas T; Deininger, Michael M; Valent, Peter P; Gleixner, Karoline V KV
A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1T315I in Ph+ CML.
Leukemia Research
Gleixner, Karoline V KV; Sadovnik, Irina I; Schneeweiss, Mathias M; Eisenwort, Gregor G; Byrgazov, Konstantin K; Stefanzl, Gabriele G; Berger, Daniela D; Herrmann, Harald H; Hadzijusufovic, Emir E; Lion, Thomas T; Valent, Peter P
Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
Asian Pacific Journal Of Cancer Prevention : Apjcp
Mat Yusoff, Yuslina Y; Abu Seman, Zahidah Z; Othman, Norodiyah N; Kamaluddin, Nor Rizan NR; Esa, Ezalia E; Zulkiply, Nor Amalina NA; Abdullah, Julia J; Zakaria, Zubaidah Z
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib.
Blood Cancer Journal
Ottmann, Oliver O; Saglio, Giuseppe G; Apperley, Jane F JF; Arthur, Christopher C; Bullorsky, Eduardo E; Charbonnier, Aude A; Dipersio, John F JF; Kantarjian, Hagop H; Khoury, Hanna Jean HJ; Kim, Dong-Wook DW; Healey, Diane D; Strauss, Lewis L; Cortes, Jorge E JE
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Haematologica
Gambacorti-Passerini, Carlo C; Cortes, Jorge E JE; Lipton, Jeff H JH; Kantarjian, Hagop M HM; Kim, Dong-Wook DW; Schafhausen, Philippe P; Crescenzo, Rocco R; Bardy-Bouxin, Nathalie N; Shapiro, Mark M; Noonan, Kay K; Leip, Eric E; DeAnnuntis, Liza L; Brümmendorf, Tim H TH; Khoury, H Jean HJ
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
Cancer
Jain, Preetesh P; Kantarjian, Hagop M HM; Ghorab, Ahmad A; Sasaki, Koji K; Jabbour, Elias J EJ; Nogueras Gonzalez, Graciela G; Kanagal-Shamanna, Rashmi R; Issa, Ghayas C GC; Garcia-Manero, Guillermo G; Kc, Devendra D; Dellasala, Sara S; Pierce, Sherry S; Konopleva, Marina M; Wierda, William G WG; Verstovsek, Srdan S; Daver, Naval G NG; Kadia, Tapan M TM; Borthakur, Gautam G; O'Brien, Susan S; Estrov, Zeev Z; Ravandi, Farhad F; Cortes, Jorge E JE
Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Cancer Biology & Therapy
Akram, Afia Muhammad AM; Iqbal, Zafar Z; Akhtar, Tanveer T; Khalid, Ahmed Mukhtar AM; Sabar, Muhammad Farooq MF; Qazi, Mahmood Hussain MH; Aziz, Zeba Z; Sajid, Nadia N; Aleem, Aamer A; Rasool, Mahmood M; Asif, Muhammad M; Aloraibi, Saleh S; Aljamaan, Khaled K; Iqbal, Mudassar M
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.
Haematologica
Cortes, Jorge J; Talpaz, Moshe M; Smith, Hedy P HP; Snyder, David S DS; Khoury, Jean J; Bhalla, Kapil N KN; Pinilla-Ibarz, Javier J; Larson, Richard R; Mitchell, David D; Wise, Scott C SC; Rutkoski, Thomas J TJ; Smith, Bryan D BD; Flynn, Daniel L DL; Kantarjian, Hagop M HM; Rosen, Oliver O; Van Etten, Richard A RA
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib.
American Journal Of Hematology
Cortes, Jorge E JE; Khoury, Hanna J HJ; Kantarjian, Hagop M HM; Lipton, Jeff H JH; Kim, Dong-Wook DW; Schafhausen, Philippe P; Matczak, Ewa E; Leip, Eric E; Noonan, Kay K; Brümmendorf, Tim H TH; Gambacorti-Passerini, Carlo C
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Bmc Cancer
Soverini, Simona S; De Benedittis, Caterina C; Castagnetti, Fausto F; Gugliotta, Gabriele G; Mancini, Manuela M; Bavaro, Luana L; Machova Polakova, Katerina K; Linhartova, Jana J; Iurlo, Alessandra A; Russo, Domenico D; Pane, Fabrizio F; Saglio, Giuseppe G; Rosti, Gianantonio G; Cavo, Michele M; Baccarani, Michele M; Martinelli, Giovanni G
Differential clinical and prognostic impact of myeloid sarcoma vs medullary myeloid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Blood Cancer Journal
Chen, Z Z; Wang, W W; Cortes, J E JE; Liu, E E; Miranda, R N RN; Zhao, C C; Yuan, J J; Lu, X X; Yang, W W; Ameri, M D MD; Kantarjian, H M HM; Medeiros, L J LJ; Hu, S S
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Leukemia
Hochhaus, A A; Saglio, G G; Hughes, T P TP; Larson, R A RA; Kim, D-W DW; Issaragrisil, S S; le Coutre, P D PD; Etienne, G G; Dorlhiac-Llacer, P E PE; Clark, R E RE; Flinn, I W IW; Nakamae, H H; Donohue, B B; Deng, W W; Dalal, D D; Menssen, H D HD; Kantarjian, H M HM
Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Sadovnik, Irina I; Hoelbl-Kovacic, Andrea A; Herrmann, Harald H; Eisenwort, Gregor G; Cerny-Reiterer, Sabine S; Warsch, Wolfgang W; Hoermann, Gregor G; Greiner, Georg G; Blatt, Katharina K; Peter, Barbara B; Stefanzl, Gabriele G; Berger, Daniela D; Bilban, Martin M; Herndlhofer, Susanne S; Sill, Heinz H; Sperr, Wolfgang R WR; Streubel, Berthold B; Mannhalter, Christine C; Holyoake, Tessa L TL; Sexl, Veronika V; Valent, Peter P
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
American Journal Of Hematology
Gambacorti-Passerini, Carlo C; Kantarjian, Hagop M HM; Kim, Dong-Wook DW; Khoury, Hanna J HJ; Turkina, Anna G AG; Brümmendorf, Tim H TH; Matczak, Ewa E; Bardy-Bouxin, Nathalie N; Shapiro, Mark M; Turnbull, Kathleen K; Leip, Eric E; Cortes, Jorge E JE
A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
Plos One
Augis, Vanessa V; Airiau, Kelly K; Josselin, Marina M; Turcq, Béatrice B; Mahon, François-Xavier FX; Belloc, Francis F